New drug combo aims to improve outcomes for elderly lymphoma patients
NCT ID NCT05245656
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether alternating two chemotherapy regimens (RB and RBAC) works better than the standard RB regimen alone for elderly patients newly diagnosed with mantle cell lymphoma who are not eligible for a stem cell transplant. About 90 participants will be randomly assigned to one of the two treatment groups. The study measures how long the cancer stays under control, overall survival, and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rituximab, Bendamustine, and Cytarabine (chemotherapy drugs)
What this could lead to
If this works, it could offer a more effective first-line treatment option for elderly patients with mantle cell lymphoma who cannot undergo a stem cell transplant.
What could go wrong
This is a phase 2 trial with only 90 participants, so results are preliminary. Adding cytarabine may increase side effects, and the benefit over standard therapy is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Samsung Medical Center
RECRUITINGSeoul, Gangnam-Gu, 06351, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••